Blue Jet Healthcare announced its Q2 and H1 FY26 financial results. Revenue from operations for Q2 stood at Rs. 1,655 mn, with an EBITDA of Rs. 549 mn. For H1 FY26, revenue from operations reached Rs. 5,202 mn, and EBITDA was Rs. 1,759 mn. The company saw robust growth in its Pharma Intermediates segment and continues to focus on operational efficiency.
Financial Performance Highlights
The company reported the following key financial results:
- Q2 FY26:
Revenue from Operations: Rs. 1,655 mn
EBITDA: Rs. 549 mn (33% Margin)
PAT: Rs. 521 mn (32% Margin)
- H1 FY26:
Revenue from Operations: Rs. 5,202 mn
EBITDA: Rs. 1,759 mn (34% Margin)
PAT: Rs. 1,433 mn (28% Margin)
Segment Performance
The company saw an increase in revenue from operations in H1 FY26 driven by an increase in sales of Pharma Intermediates.
Key Business Updates
A new lodinated-based advance contrast media intermediate product was launched and dispatched in July 2025. The company also reports strong growth in regulated markets for its NCE – Contrast media for MRI Segment.
Strategic Developments
Payment has been made for the acquisition of 102 acres of land near Vizag. Capex investment of over Rs. 82 crore was incurred during the period from April 2025 to September 2025.
Shareholding Pattern
As of September 30, 2025, Promoters hold 79.8% of the company, DII holds 3.6%, FII holds 1.8% and Others hold the remaining 14.7%.
Source: BSE